坐剤市場 – 2030年までの世界予測

本レポートは、坐剤市場を種類、基剤、処方、用途、患者タイプ、地域別に分析しています。また、市場成長に影響を与える要因（促進要因、抑制要因、機会、課題など）を分析するとともに、市場リーダー企業の競争環境の詳細も提供しています。さらに、マイクロマーケットを個々の成長傾向に基づいて分析し、5つの主要地域（および各地域に属する国）における市場セグメントの収益予測も示しています。

世界の坐剤市場は、予測期間中に4.7%のCAGRで成長し、2025年の16億3,000万米ドルから2030年には25億6,000万米ドルに達すると予測されています。

The global suppositories market is projected to reach USD 2.56 billion by 2030 from USD 1.63 billion in 2025, at a CAGR of 4.7% during the forecast period.

The significant expansion of the geriatric demographic worldwide, coupled with the escalating prevalence of chronic conditions such as gastrointestinal diseases, hemorrhoids, and inflammatory bowel diseases, is poised to drive the demand for the suppositories market. Additionally, the increasing focus on preventive healthcare, coupled with rising healthcare expenditures and improvements in healthcare infrastructure across various regions, also facilitates market growth. Investments in healthcare infrastructure and initiatives to improve the accessibility and affordability of suppositories are also likely to bolster the market growth of suppositories.

The rectal suppositories segment is expected to grow at the highest CAGR during the forecast period.

The rectal suppositories segment is projected to grow with the highest CAGR in the suppositories market. The growth is primarily attributed to the effectiveness of the rectal suppositories in delivering rapid relief for common conditions such as pain, fever, inflammation, and constipation. They are widely used by geriatric and pediatric patients who often face swallowing problems. Moreover, the increasing demand for patient-friendly, targeted drug delivery formulations are boosting the adoption of rectal suppositories in various settings, thereby driving the market growth.

The over-the-counter (OTC) segment is expected to command the highest CAGR during the forecast period.

Based on prescription, the suppositories market is segmented into over-the-counter (OTC) and prescribed suppositories. The over-the-counter (OTC) segment is anticipated to grow at a faster rate due to increasing preferences for self-care solutions and easy accessibility of common treatment options. OTC suppositories, such as glycerin for constipation, and herbal hemorrhoid suppositories are widely available through retailers and online platforms. Moreover, increasing awareness about self-medication at home care increasingly demands OTC suppositories, thereby fueling the global market growth.

The aqueous/hydrophilic base segment is expected to have the highest CAGR during the forecast period.

The suppositories market by base is categorized into oleaginous/lipophilic bases, aqueous/hydrophilic bases, and emulsifying bases. The aqueous/ hydrophilic base segment accounted for the fastest growth rate during the forecast period. Compared to the traditional oleaginous (fat-based) bases, hydrophilic bases (e.g., polyethylene glycol (PEG) and glycerinated gelatins) provide a lot of flexibility and stability in formulations, especially for drugs that cannot tolerate melting. Hydrophilic bases are not greasy and constitute higher acceptability for the patient, driving their demand and market growth.

North America accounted for the largest regional share of the suppositories market in 2024.

The global suppositories market is segmented into five major regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America is the largest regional market for suppositories, whereas the Asia Pacific market is estimated to grow at the highest CAGR during the forecast period.

The significant predominance of the North American market can largely be attributed to several interrelated factors. Firstly, a rising incidence of acute and chronic diseases has become a pressing public health concern and is driving demand for related healthcare services and products. This increase is further supported by a robust and well-established healthcare infrastructure that efficiently provides medical care and resources to address these health challenges. Furthermore, leading pharmaceutical companies and manufacturers based in the US and Canada drive consistent product availability and sustained-release technologies in the region. Together, these factors create a strong environment for market growth for suppositories.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1–35%, Tier 2–40%, and Tier 3– 25%
• By Designation: C-level–30%, Director-level–23%, and Other Designations–47%
• By Region: North America–35%, Europe–20%, Asia Pacific–25%, Latin America–13%, and Middle East & Africa–7%

The major players operating in the suppositories market are Bayer AG (Germany), Novartis AG (Switzerland), Sanofi (France), Zydus Group (India), Bliss GVS Pharma Limited (India), Church & Dwight Co., Inc. (US), Bausch Health Companies Inc. (Canada), Teva Pharmaceutical Industries Ltd. (Israel), Sun Pharmaceutical Industries Ltd. (India), Adcock Ingram (South Africa), Aspen Holdings (South Africa), Julphar (UAE), Cipla (India), Haleon Group of Companies (UK), and Prestige Consumer Healthcare (US).

Research Coverage

This report studies the suppositories market based on type, base, prescription, application, patient type, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).

Reasons to Buy the Report

The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to gain a larger market share. Firms purchasing the report could use one or a combination of the following strategies for strengthening their market presence.

This report provides insights into the following points:

Analysis of key drivers (rise in prevalence of acute and chronic disorders, rapidly expanding global aging population and subsequent surge in chronic disorders, ability to bypass the hepatic first-pass metabolism and therapeutic advantages, and growing demand for targeted drug delivery solutions), restraints (stringent regulatory requirements, development of innovative and more targeted drug delivery technologies, low patient and caregiver acceptance), opportunities (advancements in formulation technologies to offer high-growth opportunities, and expanding therapeutic applications), challenges (complexity of formulation and drug delivery, and limited shelf life of suppositories)

• Market Penetration: Comprehensive information on the product portfolios offered by the top players in the suppositories market
• Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the suppositories market
• Market Development: Comprehensive information on lucrative emerging regions
• Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the suppositories market
• Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.

Table of Contents

1               INTRODUCTION              25

1.1           STUDY OBJECTIVES       25

1.2           MARKET DEFINITION   25

1.3           STUDY SCOPE   26

1.3.1        MARKET SEGMENTATION AND REGIONAL SCOPE                 26

1.3.2        INCLUSIONS AND EXCLUSIONS 27

1.3.3        YEARS CONSIDERED      28

1.4           CURRENCY CONSIDERED            28

1.5           STAKEHOLDERS               29

2               RESEARCH METHODOLOGY       30

2.1           RESEARCH DATA              30

2.1.1        SECONDARY DATA          31

2.1.1.1    Key data from secondary sources       32

2.1.2        PRIMARY DATA 32

2.1.2.1    Primary sources    33

2.1.2.2    Key industry insights           34

2.1.2.3    Breakdown of primary interviews      34

2.2           MARKET SIZE ESTIMATION         35

2.2.1        REVENUE SHARE ANALYSIS (BOTTOM-UP APPROACH)                 36

2.2.2        COMPANY INVESTOR PRESENTATIONS AND PRIMARY INTERVIEWS      36

2.2.3        TOP-DOWN APPROACH                37

2.2.4        BOTTOM-UP APPROACH              37

2.2.5        PRIMARY INTERVIEWS  38

2.3           GROWTH FORECAST MODEL     38

2.4           DATA TRIANGULATION                39

2.5           RESEARCH ASSUMPTIONS           40

2.6           RESEARCH LIMITATIONS             40

2.7           RISK ANALYSIS  41

3               EXECUTIVE SUMMARY  42

4               PREMIUM INSIGHTS       46

4.1           SUPPOSITORIES MARKET OVERVIEW     46

4.2           NORTH AMERICA: SUPPOSITORIES MARKET, BY TYPE AND COUNTRY 47

4.3           SUPPOSITORIES MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION)            47

4.4           SUPPOSITORIES MARKET, BY BASE, 2025 VS. 2030 (USD MILLION)            48

4.5           SUPPOSITORIES MARKET, BY PRESCRIPTION, 2025 VS. 2030 (USD MILLION)       48

4.6           SUPPOSITORIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES              49

5               MARKET OVERVIEW       50

5.1           INTRODUCTION              50

5.2           MARKET DYNAMICS       50

5.2.1        DRIVERS               51

5.2.1.1    Increasing prevalence of acute and chronic disorders    51

5.2.1.2    Booming geriatric population worldwide          51

5.2.1.3    Pharmacokinetic advantages of suppositories 52

5.2.1.4    Growing demand for targeted and localized drug delivery solutions 52

5.2.2        RESTRAINTS      53

5.2.2.1    Stringent regulatory requirements     53

5.2.2.2    Rapid development of innovative drug delivery technologies                 53

5.2.2.3    Low patient and caregiver acceptance               54

5.2.3        OPPORTUNITIES              54

5.2.3.1    Emerging formulations and 3D techniques      54

5.2.3.2    Expanding therapeutic applications  54

5.2.4        CHALLENGES    55

5.2.4.1    Complex formulation and drug delivery            55

5.2.4.2    Limited shelf life of suppositories      55

5.3           TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS            56

5.4           PRICING ANALYSIS          56

5.4.1        AVERAGE SELLING PRICE TREND, BY KEY PLAYER                 56

5.4.2        AVERAGE SELLING PRICE TREND, BY REGION   58

5.5           VALUE CHAIN ANALYSIS               58

5.6           ECOSYSTEM ANALYSIS  60

5.7           INVESTMENT AND FUNDING SCENARIO               61

5.8           TECHNOLOGY ANALYSIS             62

5.8.1        KEY TECHNOLOGIES     62

5.8.1.1    3D printed multi-drug-loaded suppositories   62

5.8.1.2    Self-microemulsifying suppository systems     63

5.8.2        COMPLEMENTARY TECHNOLOGIES       63

5.8.2.1    Mucoadhesive and bioadhesive polymers         63

5.8.3        ADJACENT TECHNOLOGIES       64

5.8.3.1    Form-fill-seal (FFS) machine technology         64

5.9           PATENT ANALYSIS          64

5.9.1        PATENT PUBLICATION TRENDS FOR SUPPOSITORIES                 64

5.9.2        JURISDICTION AND TOP APPLICANT ANALYSIS                 66

5.10         TRADE ANALYSIS             67

5.10.1      IMPORT DATA  67

5.10.2      EXPORT DATA  68

5.11         KEY CONFERENCES AND EVENTS, 2025–2026        68

5.12         REGULATORY LANDSCAPE         69

5.12.1      REGULATORY FRAMEWORK       69

5.12.1.1  North America      69

5.12.1.1.1                US           69

5.12.1.1.2                Canada   70

5.12.1.2  Europe   70

5.12.1.2.1                Germany                 70

5.12.1.2.2                Italy         70

5.12.1.2.3                France    70

5.12.1.2.4                UK          70

5.12.1.3  Asia Pacific            71

5.12.1.3.1                China      71

5.12.1.3.2                Japan      71

5.12.1.3.3                India       71

5.12.1.3.4                South Korea           71

5.12.1.3.5                Australia 71

5.12.1.4  Latin America       72

5.12.1.5  Middle East & Africa            72

5.12.2      REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS             72

5.13         PORTER’S FIVE FORCES ANALYSIS           75

5.13.1      BARGAINING POWER OF SUPPLIERS       76

5.13.2      BARGAINING POWER OF BUYERS             76

5.13.3      THREAT OF NEW ENTRANTS      76

5.13.4      THREAT OF SUBSTITUTES          76

5.13.5      INTENSITY OF COMPETITIVE RIVALRY 77

5.14         KEY STAKEHOLDERS AND BUYING CRITERIA     77

5.14.1      KEY STAKEHOLDERS IN BUYING PROCESS           77

5.14.2      KEY BUYING CRITERIA  78

5.15         UNMET NEEDS/END-USER EXPECTATIONS         79

5.16         IMPACT OF AI/GEN AI   80

5.16.1      INTRODUCTION              80

5.16.2      MARKET POTENTIAL OF AI ON SUPPOSITORIES MARKET               80

5.16.3      AI USE CASES     81

5.16.4      FUTURE OF GENERATIVE AI IN SUPPOSITORIES MARKET               81

5.17         IMPACT OF 2025 US TARIFF         82

5.17.1      INTRODUCTION              82

5.17.2      KEY TARIFF RATES          83

5.17.3      PRICE IMPACT ANALYSIS             84

5.17.4      IMPACT ON COUNTRY/REGION                84

5.17.5      IMPACT ON END-USER INDUSTRIES       85

6               SUPPOSITORIES MARKET, BY TYPE         86

6.1           INTRODUCTION              87

6.2           RECTAL SUPPOSITORIES              87

6.2.1        EASE OF USE, AFFORDABILITY, AND QUICK RELIEF TO PROMOTE GROWTH      87

6.3           VAGINAL SUPPOSITORIES           89

6.3.1        SHORT-TERM THERAPY AND QUICK SYMPTOM RELIEF TO AUGMENT GROWTH               89

6.4           URETHRAL SUPPOSITORIES       92

6.4.1        NEED FOR LOCALIZED, FAST-ACTING THERAPY TO CONTRIBUTE TO GROWTH         92

7               SUPPOSITORIES MARKET, BY BASE         94

7.1           INTRODUCTION              95

7.2           OLEAGINOUS/ LIPOPHILIC BASES           95

7.2.1        RISING PATIENT PREFERENCE FOR EASY-TO-USE, NON-ORAL DOSAGE FORMS TO FACILITATE GROWTH             95

7.3           AQUEOUS/HYDROPHILIC BASES              96

7.3.1        NEED TO MAINTAIN DRUG STABILITY TO SPUR GROWTH             96

7.4           EMULSIFYING BASES      98

7.4.1        CONSISTENT DRUG RELEASE AND ABSORPTION TO BOLSTER GROWTH         98

8               SUPPOSITORIES MARKET, BY PRESCRIPTION     100

8.1           INTRODUCTION              101

8.2           PRESCRIBED SUPPOSITORIES    101

8.2.1        INCREASED RELIANCE ON PRESCRIPTION SUPPOSITORIES FOR HORMONE REPLACEMENT AND ANTIEMETIC TREATMENT TO SUPPORT GROWTH          101

8.3           OVER-THE-COUNTER SUPPOSITORIES 103

8.3.1        GROWING PREFERENCE FOR CONVENIENT, NON-INVASIVE RELIEF FROM COMMON HEALTH CONCERNS TO FUEL MARKET   103

9               SUPPOSITORIES MARKET, BY APPLICATION       105

9.1           INTRODUCTION              106

9.2           HEMORRHOID TREATMENTS    106

9.2.1        INCREASING OBESITY AND SEDENTARY LIFESTYLE TO EXPEDITE GROWTH       106

9.3           ANTI-BACTERIAL AND ANTI-FUNGAL APPLICATIONS                 107

9.3.1        GROWING BURDEN OF VAGINAL INFECTIONS TO PROPEL MARKET             107

9.4           ANALGESICS & ANTIPYRETICS  109

9.4.1        INCREASING INCIDENCE OF CHRONIC PAIN CONDITIONS TO ACCELERATE GROWTH             109

9.5           LAXATIVES         110

9.5.1        LOW DIETARY FIBER INTAKE AND RISING PREVALENCE OF CONSTIPATION TO BOOST MARKET                110

9.6           ANTI-EMETICS 112

9.6.1        GROWING USE OF ANTI-EMETIC SUPPOSITORIES FOR CHEMOTHERAPY, RADIATION THERAPY, OR POST-OPERATIVE RECOVERY TO DRIVE MARKET  112

9.7           OTHER APPLICATIONS 113

10            SUPPOSITORIES MARKET, BY PATIENT TYPE     115

10.1         INTRODUCTION              116

10.2         ADULT PATIENTS            116

10.2.1      GROWING FOCUS ON CHRONIC CONDITION MANAGEMENT TO DRIVE MARKET         116

10.3         PEDIATRIC PATIENTS   117

10.3.1      INCREASING NEED FOR ALTERNATIVE DRUG DELIVERY TO SUPPORT GROWTH 117

10.4         GERIATRIC PATIENTS   119

10.4.1      NEED FOR RELIABLE, EFFECTIVE, AND WELL-TOLERATED DRUG DELIVERY IN ELDERLY PATIENTS TO AID GROWTH             119

11            SUPPOSITORIES MARKET, BY REGION   121

11.1         INTRODUCTION              122

11.2         NORTH AMERICA             123

11.2.1      MACROECONOMIC OUTLOOK FOR NORTH AMERICA                 123

11.2.2      US           126

11.2.2.1  Rising demand for non-oral therapeutics among aging and chronic patient groups to augment growth       126

11.2.3      CANADA               129

11.2.3.1  Government support and public health campaigns to encourage growth    129

11.3         EUROPE               131

11.3.1      MACROECONOMIC OUTLOOK FOR EUROPE      131

11.3.2      GERMANY           134

11.3.2.1  High healthcare spending and prescription culture to support growth    134

11.3.3      FRANCE                136

11.3.3.1  Increasing use of suppositories in pediatrics, gynecology, and internal medicine to propel market   136

11.3.4      UK          138

11.3.4.1 Growing use of suppositories for pediatric fever, antiemetic needs, and constipation management to drive market                138

11.3.5      ITALY    141

11.3.5.1  Increasing pediatric patient population to contribute to growth                 141

11.3.6      SPAIN    143

11.3.6.1  Rising adoption of non-invasive, self-administered dosage forms to spur growth       143

11.3.7      REST OF EUROPE             145

11.4         ASIA PACIFIC     148

11.4.1      MACROECONOMIC OUTLOOK FOR ASIA PACIFIC                 148

11.4.2      JAPAN   152

11.4.2.1  Geriatric population and regulatory guidelines to drive market                 152

11.4.3      CHINA  154

11.4.3.1  Expanding elderly population to boost market                 154

11.4.4      INDIA    156

11.4.4.1  Increasing healthcare penetration across urban and semi-urban areas to promote growth      156

11.4.5      AUSTRALIA         159

11.4.5.1  Increased patient volume and favorable government initiatives to sustain growth       159

11.4.6      SOUTH KOREA  161

11.4.6.1  Favorable insurance policy to accelerate growth              161

11.4.7      REST OF ASIA PACIFIC   163

11.5         LATIN AMERICA                165

11.5.1      MACROECONOMIC OUTLOOK FOR LATIN AMERICA                 165

11.5.2      BRAZIL 168

11.5.2.1  Expanding public healthcare access and domestic manufacturing to bolster growth  168

11.5.3      MEXICO                170

11.5.3.1  Growing consumer preference for self-medication to propel market    170

11.5.4      REST OF LATIN AMERICA             172

11.6         MIDDLE EAST & AFRICA                175

11.6.1      MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 175

11.6.2      GCC COUNTRIES              177

11.6.2.1  Kingdom of Saudi Arabia (KSA)        180

11.6.2.1.1                Substantial public healthcare investment to facilitate growth    180

11.6.2.2  United Arab Emirates (UAE)             182

11.6.2.2.1                Favorable environment for drug import and local manufacturing to aid growth               182

11.6.2.3  Rest of GCC Countries        184

11.6.3      REST OF MIDDLE EAST & AFRICA             186

12            COMPETITIVE LANDSCAPE         189

12.1         INTRODUCTION              189

12.2         KEY PLAYER STRATEGIES/RIGHT TO WIN            189

12.2.1      OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN SUPPOSITORIES MARKET       189

12.3         REVENUE ANALYSIS, 2022–2024  191

12.4         MARKET SHARE ANALYSIS, 2024                 191

12.5         BRAND/PRODUCT COMPARISON             194

12.6         COMPANY VALUATION AND FINANCIAL METRICS                 195

12.7         COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024                 196

12.7.1      STARS   196

12.7.2      EMERGING LEADERS     196

12.7.3      PERVASIVE PLAYERS      196

12.7.4      PARTICIPANTS 196

12.7.5      COMPANY FOOTPRINT: KEY PLAYERS, 2024         198

12.7.5.1  Company footprint               198

12.7.5.2  Region footprint   198

12.7.5.3  Type footprint       199

12.7.5.4  Base footprint        200

12.7.5.5  Prescription footprint          201

12.8         COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024        202

12.8.1      PROGRESSIVE COMPANIES         202

12.8.2      RESPONSIVE COMPANIES            202

12.8.3      DYNAMIC COMPANIES  202

12.8.4      STARTING BLOCKS         202

12.8.5      COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024                 204

12.8.5.1  Detailed list of key startups/SMEs    204

12.8.5.2  Competitive benchmarking of key startups/SMEs          204

12.9         COMPETITIVE SCENARIO             205

12.9.1      PRODUCT APPROVALS 205

12.9.2      DEALS  205

12.9.3      EXPANSIONS     206

13            COMPANY PROFILES      207

13.1         KEY PLAYERS     207

13.1.1      SANDOZ GROUP AG       207

13.1.1.1  Business overview 207

13.1.1.2  Products offered   208

13.1.1.3  MnM view              209

13.1.1.3.1                Key strengths        209

13.1.1.3.2                Strategic choices   209

13.1.1.3.3                Weaknesses and competitive threats 209

13.1.2      TEVA PHARMACEUTICAL INDUSTRIES LTD.       210

13.1.2.1  Business overview 210

13.1.2.2  Products offered   211

13.1.2.3  MnM view              212

13.1.2.3.1                Key strengths        212

13.1.2.3.2                Strategic choices   212

13.1.2.3.3                Weaknesses and competitive threats 212

13.1.3      CIPLA    213

13.1.3.1  Business overview 213

13.1.3.2  Products offered   214

13.1.3.3  MnM view              215

13.1.3.3.1                Key strengths        215

13.1.3.3.2                Strategic choices   215

13.1.3.3.3                Weaknesses and competitive threats 215

13.1.4      SANOFI 216

13.1.4.1  Business overview 216

13.1.4.2  Products offered   217

13.1.4.3  Recent developments           218

13.1.4.3.1                Deals      218

13.1.4.4  MnM view              218

13.1.4.4.1                Key strengths        218

13.1.4.4.2                Strategic choices   218

13.1.4.4.3                Weaknesses and competitive threats 218

13.1.5      SUN PHARMACEUTICAL INDUSTRIES LTD.          219

13.1.5.1  Business overview 219

13.1.5.2  Products offered   220

13.1.5.3  Recent developments           221

13.1.5.3.1                Deals      221

13.1.5.4  MnM view              221

13.1.5.4.1                Key strengths        221

13.1.5.4.2                Strategic choices   221

13.1.5.4.3                Weaknesses and competitive threats 221

13.1.6      BAYER AG            222

13.1.6.1  Business overview 222

13.1.6.2  Products offered   223

13.1.6.3  Recent developments           224

13.1.6.3.1                Expansions             224

13.1.7      NOVARTIS AG   225

13.1.7.1  Business overview 225

13.1.7.2  Products offered   226

13.1.7.3  Recent developments           227

13.1.7.3.1                Deals      227

13.1.8      ZYDUS GROUP  228

13.1.8.1  Business overview 228

13.1.8.2  Products offered   229

13.1.8.3  Recent developments           230

13.1.8.3.1                Product approvals 230

13.1.9      BLISS GVS PHARMA LIMITED     231

13.1.9.1  Business overview 231

13.1.9.2  Products offered   232

13.1.10   CHURCH & DWIGHT CO., INC.   233

13.1.10.1                 Business overview 233

13.1.10.2                 Products offered   234

13.1.11   BAUSCH HEALTH COMPANIES INC.         235

13.1.11.1                 Business overview 235

13.1.11.2                 Products offered   237

13.1.12   ADCOCK INGRAM            238

13.1.12.1                 Business overview 238

13.1.12.2                 Products offered   239

13.1.13   ASPEN HOLDINGS           240

13.1.13.1                 Business overview 240

13.1.13.2                 Products offered   241

13.1.14   JULPHAR              242

13.1.14.1                 Business overview 242

13.1.14.2                 Products offered   243

13.1.15   HALEON GROUP OF COMPANIES             245

13.1.15.1                 Business overview 245

13.1.15.2                 Products offered   246

13.1.16   LES LABORATOIRES SERVIER     247

13.1.16.1                 Business overview 247

13.1.16.2                 Products offered   248

13.1.17   PRESTIGE CONSUMER HEALTHCARE INC.            249

13.1.17.1                 Business overview 249

13.1.17.2                 Products offered   250

13.1.18   VIATRIS INC.      252

13.1.18.1                 Business overview 252

13.1.18.2                 Products offered   253

13.1.19   GALEN LIMITED               254

13.1.19.1                 Business overview 254

13.1.19.2                 Products offered   254

13.1.20   MERIDIAN ENTERPRISES PVT. LTD.         257

13.1.20.1                 Business overview 257

13.1.20.2                 Products offered   257

13.2         OTHER PLAYERS              259

13.2.1      COSETTE PHARMACEUTICALS  259

13.2.2      FLAGSHIP            260

13.2.3      OUBARI PHARMA             261

13.2.4      LAVINA PHARMACEUTICALS PVT. LTD.                 262

13.2.5      NORWELL            263

14            APPENDIX           264

14.1         DISCUSSION GUIDE        264

14.2         KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL                267

14.3         CUSTOMIZATION OPTIONS        269

14.4         RELATED REPORTS         269

14.5         AUTHOR DETAILS           270

LIST OF TABLES

TABLE 1                SUPPOSITORIES MARKET: INCLUSIONS AND EXCLUSIONS      27

TABLE 2                EXCHANGE RATES UTILIZED FOR CONVERSION TO USD, 2021–2024           28

TABLE 3                SUPPOSITORIES MARKET: RESEARCH ASSUMPTIONS  40

TABLE 4                SUPPOSITORIES MARKET: RISK ANALYSIS                 41

TABLE 5                AVERAGE SELLING PRICE TREND OF RECTAL SUPPOSITORIES, BY KEY PLAYER, 2023–2025 (USD)           57

TABLE 6                AVERAGE SELLING PRICE TREND OF RECTAL SUPPOSITORIES, BY REGION,

2023–2025 (USD)                58

TABLE 7                SUPPOSITORIES MARKET: ROLE OF COMPANIES IN ECOSYSTEM       61

TABLE 8                SUPPOSITORIES MARKET: INNOVATIONS AND PATENT REGISTRATIONS,

2023–2025              66

TABLE 9               IMPORT DATA FOR HS CODE 3006, BY COUNTRY, 2021–2024 (USD THOUSAND)      67

TABLE 10             EXPORT DATA FOR HS CODE 3006, BY COUNTRY, 2021–2024 (USD THOUSAND)      68

TABLE 11              SUPPOSITORIES MARKET: KEY CONFERENCES AND EVENTS, 2025–2026                 68

TABLE 12              NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 72

TABLE 13              EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS           73

TABLE 14              ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 74

TABLE 15              LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 74

TABLE 16              REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 75

TABLE 17              SUPPOSITORIES MARKET: PORTER’S FIVE FORCES ANALYSIS           76

TABLE 18              INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE (%)  77

TABLE 19              KEY BUYING CRITERIA, BY TYPE               78

TABLE 20              SUPPOSITORIES MARKET: CURRENT UNMET NEEDS  79

TABLE 21              US-ADJUSTED RECIPROCAL TARIFF RATES                 83

TABLE 22              KEY PRODUCT-RELATED TARIFF EFFECTIVE FOR SUPPOSITORIES     83

TABLE 23              IMPACT ON COUNTRY/ REGION DUE TO US TARIFFS                84

TABLE 24              SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 87

TABLE 25              KEY PLAYERS PROVIDING RECTAL SUPPOSITORIES               88

TABLE 26              RECTAL SUPPOSITORIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     89

TABLE 27              KEY PLAYERS PROVIDING VAGINAL SUPPOSITORIES               90

TABLE 28              VAGINAL SUPPOSITORIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     91

TABLE 29              KEY PLAYERS PROVIDING URETHRAL SUPPOSITORIES               92

TABLE 30              URETHRAL SUPPOSITORIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     93

TABLE 31              SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION) 95

TABLE 32              SUPPOSITORIES MARKET FOR OLEAGINOUS/LIPOPHILIC BASES, BY COUNTRY, 2023–2030 (USD MILLION) 96

TABLE 33              SUPPOSITORIES MARKET FOR AQUEOUS/HYDROPHILIC BASES, BY COUNTRY, 2023–2030 (USD MILLION)            97

TABLE 34              SUPPOSITORIES MARKET FOR EMULSIFYING BASES, BY COUNTRY,

2023–2030 (USD MILLION)            99

TABLE 35              SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION)            101

TABLE 36              KEY PLAYERS PROVIDING PRESCRIBED SUPPOSITORIES               101

TABLE 37              PRESCRIBED SUPPOSITORIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     102

TABLE 38              KEY PLAYERS PROVIDING OVER-THE-COUNTER (OTC) SUPPOSITORIES           103

TABLE 39              OVER-THE-COUNTER (OTC) SUPPOSITORIES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            104

TABLE 40              SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION)            106

TABLE 41              SUPPOSITORIES MARKET FOR HEMORRHOID TREATMENTS, BY COUNTRY,

2023–2030 (USD MILLION)            107

TABLE 42              SUPPOSITORIES MARKET FOR ANTI-BACTERIAL & ANTI-FUNGAL APPLICATIONS,

BY COUNTRY, 2023–2030 (USD MILLION)               108

TABLE 43              SUPPOSITORIES MARKET FOR ANALGESICS & ANTIPYRETICS, BY COUNTRY,

2023–2030 (USD MILLION)            110

TABLE 44              SUPPOSITORIES MARKET FOR LAXATIVES, BY COUNTRY,

2023–2030 (USD MILLION)            111

TABLE 45              SUPPOSITORIES MARKET FOR ANTI-EMETICS, BY COUNTRY,

2023–2030 (USD MILLION)            113

TABLE 46              SUPPOSITORIES MARKET FOR OTHER APPLICATIONS, BY COUNTRY,

2023–2030 (USD MILLION)            114

TABLE 47              SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION)            116

TABLE 48              SUPPOSITORIES MARKET FOR ADULT PATIENTS, BY COUNTRY,

2023–2030 (USD MILLION)            117

TABLE 49              SUPPOSITORIES MARKET FOR PEDIATRIC PATIENTS, BY COUNTRY,

2023–2030 (USD MILLION)            118

TABLE 50              SUPPOSITORIES MARKET FOR GERIATRIC PATIENTS, BY COUNTRY,

2023–2030 (USD MILLION)            120

TABLE 51              SUPPOSITORIES MARKET, BY REGION, 2023–2030 (USD MILLION)       122

TABLE 52              SUPPOSITORIES MARKET FOR PRESCRIPTION, BY REGION,

2023–2030 (THOUSAND UNITS)  123

TABLE 53              NORTH AMERICA: SUPPOSITORIES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            124

TABLE 54              NORTH AMERICA: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)                125

TABLE 55              NORTH AMERICA: SUPPOSITORIES MARKET, BY PRESCRIPTION,

2023–2030 (USD MILLION)            125

TABLE 56              NORTH AMERICA: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)                125

TABLE 57              NORTH AMERICA: SUPPOSITORIES MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            126

TABLE 58              NORTH AMERICA: SUPPOSITORIES MARKET, BY PATIENT TYPE,

2023–2030 (USD MILLION)            126

TABLE 59              US: KEY MACROECONOMIC INDICATORS                 127

TABLE 60              US: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)       127

TABLE 61              US: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION)           127

TABLE 62              US: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)       128

TABLE 63              US: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION)            128

TABLE 64             US: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION)            128

TABLE 65              CANADA: KEY MACROECONOMIC INDICATORS                 129

TABLE 66              CANADA: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)            129

TABLE 67              CANADA: SUPPOSITORIES MARKET, BY PRESCRIPTION,

2023–2030 (USD MILLION)            130

TABLE 68              CANADA: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)            130

TABLE 69              CANADA: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              130

TABLE 70              CANADA: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION)            131

TABLE 71              EUROPE: SUPPOSITORIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     132

TABLE 72              EUROPE: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)            132

TABLE 73              EUROPE: SUPPOSITORIES MARKET, BY PRESCRIPTION,

2023–2030 (USD MILLION)            132

TABLE 74              EUROPE: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)            133

TABLE 75              EUROPE: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              133

TABLE 76              EUROPE: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION)            133

TABLE 77              GERMANY: KEY MACROECONOMIC INDICATORS      134

TABLE 78              GERMANY: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)            134

TABLE 79              GERMANY: SUPPOSITORIES MARKET, BY PRESCRIPTION,

2023–2030 (USD MILLION)            135

TABLE 80              GERMANY: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)            135

TABLE 81              GERMANY: SUPPOSITORIES MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            135

TABLE 82              GERMANY: SUPPOSITORIES MARKET, BY PATIENT TYPE,

2023–2030 (USD MILLION)            136

TABLE 83              FRANCE: KEY MACROECONOMIC INDICATORS                 136

TABLE 84              FRANCE: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)            137

TABLE 85              FRANCE: SUPPOSITORIES MARKET, BY PRESCRIPTION,

2023–2030 (USD MILLION)            137

TABLE 86              FRANCE: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)            137

TABLE 87              FRANCE: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              138

TABLE 88              FRANCE: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION)                138

TABLE 89              UK: KEY MACROECONOMIC INDICATORS                 139

TABLE 90              UK: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)       139

TABLE 91              UK: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION)           139

TABLE 92              UK: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)       140

TABLE 93             UK: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION)            140

TABLE 94              UK: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION)                140

TABLE 95              ITALY: KEY MACROECONOMIC INDICATORS                 141

TABLE 96              ITALY: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)            141

TABLE 97              ITALY: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION)           142

TABLE 98              ITALY: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)       142

TABLE 99              ITALY: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION               142

TABLE 100            ITALY: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION)                143

TABLE 101            SPAIN: KEY MACROECONOMIC INDICATORS                 143

TABLE 102            SPAIN: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)            144

TABLE 103            SPAIN: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION)           144

TABLE 104            SPAIN: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)       144

TABLE 105            SPAIN: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              145

TABLE 106            SPAIN: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION)                145

TABLE 107            REST OF EUROPE: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)                146

TABLE 108            REST OF EUROPE: SUPPOSITORIES MARKET, BY PRESCRIPTION,

2023–2030 (USD MILLION)            146

TABLE 109            REST OF EUROPE: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)                146

TABLE 110            REST OF EUROPE: SUPPOSITORIES MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            147

TABLE 111            REST OF EUROPE: SUPPOSITORIES MARKET, BY PATIENT TYPE,

2023–2030 (USD MILLION)            147

TABLE 112            ASIA PACIFIC: SUPPOSITORIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     150

TABLE 113            ASIA PACIFIC: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)                150

TABLE 114            ASIA PACIFIC: SUPPOSITORIES MARKET, BY PRESCRIPTION,

2023–2030 (USD MILLION)            150

TABLE 115            ASIA PACIFIC: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)                151

TABLE 116            ASIA PACIFIC: SUPPOSITORIES MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            151

TABLE 117            ASIA PACIFIC: SUPPOSITORIES MARKET, BY PATIENT TYPE,

2023–2030 (USD MILLION)            151

TABLE 118            JAPAN: KEY MACROECONOMIC INDICATORS                 152

TABLE 119            JAPAN: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)            152

TABLE 120            JAPAN: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION)           153

TABLE 121            JAPAN: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)            153

TABLE 122            JAPAN: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              153

TABLE 123            JAPAN: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION)                154

TABLE 124            CHINA: KEY MACROECONOMIC INDICATORS                 154

TABLE 125            CHINA: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)            155

TABLE 126            CHINA: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION)           155

TABLE 127            CHINA: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)            155

TABLE 128            CHINA: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              156

TABLE 129            CHINA: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION)                156

TABLE 130            INDIA: KEY MACROECONOMIC INDICATORS                 157

TABLE 131            INDIA: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)       157

TABLE 132            INDIA: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION)           157

TABLE 133            INDIA: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)       158

TABLE 134            INDIA: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              158

TABLE 135            INDIA: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION)                158

TABLE 136            AUSTRALIA: KEY MACROECONOMIC INDICATORS      159

TABLE 137            AUSTRALIA: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)            159

TABLE 138            AUSTRALIA: SUPPOSITORIES MARKET, BY PRESCRIPTION,

2023–2030 (USD MILLION)            160

TABLE 139            AUSTRALIA: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)            160

TABLE 140            AUSTRALIA: SUPPOSITORIES MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            160

TABLE 141            AUSTRALIA: SUPPOSITORIES MARKET, BY PATIENT TYPE,

2023–2030 (USD MILLION)            161

TABLE 142            SOUTH KOREA: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)                161

TABLE 143            SOUTH KOREA: SUPPOSITORIES MARKET, BY PRESCRIPTION,

2023–2030 (USD MILLION)            162

TABLE 144            SOUTH KOREA: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)                162

TABLE 145            SOUTH KOREA: SUPPOSITORIES MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            162

TABLE 146            SOUTH KOREA: SUPPOSITORIES MARKET, BY PATIENT TYPE,

2023–2030 (USD MILLION)            163

TABLE 147            REST OF ASIA PACIFIC: SUPPOSITORIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            163

TABLE 148            REST OF ASIA PACIFIC: SUPPOSITORIES MARKET, BY PRESCRIPTION,

2023–2030 (USD MILLION)            164

TABLE 149            REST OF ASIA PACIFIC: SUPPOSITORIES MARKET, BY BASE,

2023–2030 (USD MILLION)            164

TABLE 150            REST OF ASIA PACIFIC: SUPPOSITORIES MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            164

TABLE 151            REST OF ASIA PACIFIC: SUPPOSITORIES MARKET, BY PATIENT TYPE,

2023–2030 (USD MILLION)            165

TABLE 152            LATIN AMERICA: SUPPOSITORIES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            166

TABLE 153            LATIN AMERICA: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)                166

TABLE 154            LATIN AMERICA: SUPPOSITORIES MARKET, BY PRESCRIPTION,

2023–2030 (USD MILLION)            166

TABLE 155            LATIN AMERICA: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)                167

TABLE 156            LATIN AMERICA: SUPPOSITORIES MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            167

TABLE 157            LATIN AMERICA: SUPPOSITORIES MARKET, BY PATIENT TYPE,

2023–2030 (USD MILLION)            167

TABLE 158            BRAZIL: KEY MACROECONOMIC INDICATORS                 168

TABLE 159            BRAZIL: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)            168

TABLE 160            BRAZIL: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION)           169

TABLE 161            BRAZIL: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)            169

TABLE 162            BRAZIL: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              169

TABLE 163            BRAZIL: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION)                170

TABLE 164            MEXICO: KEY MACROECONOMIC INDICATORS                 170

TABLE 165            MEXICO: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)            171

TABLE 166            MEXICO: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION)           171

TABLE 167            MEXICO: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)            171

TABLE 168            MEXICO: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              172

TABLE 169            MEXICO: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION)                172

TABLE 170            REST OF LATIN AMERICA: SUPPOSITORIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            173

TABLE 171            REST OF LATIN AMERICA: SUPPOSITORIES MARKET, BY PRESCRIPTION,

2023–2030 (USD MILLION)            173

TABLE 172            REST OF LATIN AMERICA: SUPPOSITORIES MARKET, BY BASE,

2023–2030 (USD MILLION)            173

TABLE 173            REST OF LATIN AMERICA: SUPPOSITORIES MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            174

TABLE 174            REST OF LATIN AMERICA: SUPPOSITORIES MARKET, BY PATIENT TYPE,

2023–2030 (USD MILLION)            174

TABLE 175            MIDDLE EAST & AFRICA: SUPPOSITORIES MARKET, BY REGION,

2023–2030 (USD MILLION)            175

TABLE 176            MIDDLE EAST & AFRICA: SUPPOSITORIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            176

TABLE 177            MIDDLE EAST & AFRICA: SUPPOSITORIES MARKET, BY PRESCRIPTION,

2023–2030 (USD MILLION)            176

TABLE 178            MIDDLE EAST & AFRICA: SUPPOSITORIES MARKET, BY BASE,

2023–2030 (USD MILLION)            176

TABLE 179            MIDDLE EAST & AFRICA: SUPPOSITORIES MARKET, BY APPLICATION

2023–2030 (USD MILLION)            177

TABLE 180            MIDDLE EAST & AFRICA: SUPPOSITORIES MARKET, BY PATIENT TYPE,

2023–2030 (USD MILLION)            177

TABLE 181            GCC COUNTRIES: SUPPOSITORIES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            178

TABLE 182            GCC COUNTRIES: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)                178

TABLE 183            GCC COUNTRIES: SUPPOSITORIES MARKET, BY PRESCRIPTION,

2023–2030 (USD MILLION)            178

TABLE 184            GCC COUNTRIES: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)                179

TABLE 185            GCC COUNTRIES: SUPPOSITORIES MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            179

TABLE 186            GCC COUNTRIES: SUPPOSITORIES MARKET, BY PATIENT TYPE,

2023–2030 (USD MILLION)            179

TABLE 187            KINGDOM OF SAUDI ARABIA (KSA): KEY MACROECONOMIC INDICATORS              180

TABLE 188            KINGDOM OF SAUDI ARABIA (KSA): SUPPOSITORIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            180

TABLE 189            KINGDOM OF SAUDI ARABIA (KSA): SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION)            181

TABLE 190            KINGDOM OF SAUDI ARABIA (KSA): SUPPOSITORIES MARKET, BY BASE,

2023–2030 (USD MILLION)            181

TABLE 191            KINGDOM OF SAUDI ARABIA (KSA): SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION)            181

TABLE 192            KINGDOM OF SAUDI ARABIA (KSA): SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION)            182

TABLE 193            UAE: KEY MACROECONOMIC INDICATORS                 182

TABLE 194            UAE: SUPPOSITORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)       183

TABLE 195            UAE: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION)           183

TABLE 196            UAE: SUPPOSITORIES MARKET, BY BASE, 2023–2030 (USD MILLION)       183

TABLE 197            UAE: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              184

TABLE 198            UAE: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION)                184

TABLE 199            REST OF GCC COUNTRIES: SUPPOSITORIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            185

TABLE 200            REST OF GCC COUNTRIES: SUPPOSITORIES MARKET, BY PRESCRIPTION,

2023–2030 (USD MILLION)            185

TABLE 201            REST OF GCC COUNTRIES: SUPPOSITORIES MARKET, BY BASE,

2023–2030 (USD MILLION)            185

TABLE 202            REST OF GCC COUNTRIES: SUPPOSITORIES MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            186

TABLE 203            REST OF GCC COUNTRIES: SUPPOSITORIES MARKET, BY PATIENT TYPE,

2023–2030 (USD MILLION)            186

TABLE 204            REST OF MIDDLE EAST & AFRICA: SUPPOSITORIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            187

TABLE 205            REST OF MIDDLE EAST & AFRICA: SUPPOSITORIES MARKET, BY PRESCRIPTION, 2023–2030 (USD MILLION)            187

TABLE 206            REST OF MIDDLE EAST & AFRICA: SUPPOSITORIES MARKET, BY BASE,

2023–2030 (USD MILLION)            187

TABLE 207            REST OF MIDDLE EAST & AFRICA: SUPPOSITORIES MARKET, BY APPLICATION, 2023–2030 (USD MILLION)            188

TABLE 208            REST OF MIDDLE EAST & AFRICA: SUPPOSITORIES MARKET, BY PATIENT TYPE, 2023–2030 (USD MILLION)            188

TABLE 209            OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN

SUPPOSITORIES MARKET             189

TABLE 210            SUPPOSITORIES MARKET: DEGREE OF COMPETITION, 2024       192

TABLE 211            SUPPOSITORIES MARKET: REGION FOOTPRINT                 198

TABLE 212            SUPPOSITORIES MARKET: TYPE FOOTPRINT                 199

TABLE 213            SUPPOSITORIES MARKET: BASE FOOTPRINT                 200

TABLE 214            SUPPOSITORIES MARKET: PRESCRIPTION FOOTPRINT       201

TABLE 215            SUPPOSITORIES MARKET: DETAILED LIST OF KEY STARTUPS/SMES    204

TABLE 216            SUPPOSITORIES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES          204

TABLE 217            SUPPOSITORIES MARKET: PRODUCT APPROVALS, JANUARY 2022–MAY 2025    205

TABLE 218            SUPPOSITORIES MARKET: DEALS, JANUARY 2022–MAY 2025   205

TABLE 219            SUPPOSITORIES MARKET: EXPANSIONS, JANUARY 2022–MAY 2025               206

TABLE 220            SANDOZ GROUP AG: COMPANY OVERVIEW                 207

TABLE 221            SANDOZ GROUP AG: PRODUCTS OFFERED                 208

TABLE 222            TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW   210

TABLE 223            TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED    211

TABLE 224            CIPLA: COMPANY OVERVIEW    213

TABLE 225            CIPLA: PRODUCTS OFFERED     214

TABLE 226            SANOFI: COMPANY OVERVIEW 216

TABLE 227            SANOFI: PRODUCTS OFFERED  217

TABLE 228            SANOFI: DEALS, JANUARY 2022–MAY 2025                 218

TABLE 229            SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW   219

TABLE 230            SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED    220

TABLE 231            SUN PHARMACEUTICAL INDUSTRIES LTD.: DEALS, JANUARY 2022–MAY 2025                221

TABLE 232            BAYER AG: COMPANY OVERVIEW             222

TABLE 233            BAYER AG: PRODUCTS OFFERED              223

TABLE 234            BAYER AG: EXPANSIONS, JANUARY 2022–MAY 2025        224

TABLE 235            NOVARTIS AG: COMPANY OVERVIEW    225

TABLE 236            NOVARTIS AG: PRODUCTS OFFERED     226

TABLE 237            NOVARTIS AG: DEALS, JANUARY 2022–MAY 2025                 227

TABLE 238            ZYDUS GROUP: COMPANY OVERVIEW  228

TABLE 239            ZYDUS GROUP: PRODUCTS OFFERED   229

TABLE 240            ZYDUS GROUP: PRODUCT APPROVALS, JANUARY 2022–MAY 2025               230

TABLE 241            BLISS GVS PHARMA LIMITED: COMPANY OVERVIEW          231

TABLE 242            BLISS GVS PHARMA LIMITED: PRODUCTS OFFERED             232

TABLE 243            CHURCH & DWIGHT CO., INC.: COMPANY OVERVIEW          233

TABLE 244            CHURCH & DWIGHT CO., INC.: PRODUCTS OFFERED             234

TABLE 245            BAUSCH HEALTH COMPANIES INC.: COMPANY OVERVIEW          235

TABLE 246            BAUSCH HEALTH COMPANIES INC.: PRODUCTS OFFERED             237

TABLE 247            ADCOCK INGRAM: COMPANY OVERVIEW                 238

TABLE 248            ADCOCK INGRAM: PRODUCTS OFFERED                 239

TABLE 249            ASPEN HOLDINGS: COMPANY OVERVIEW                 240

TABLE 250            ASPEN HOLDINGS: PRODUCTS OFFERED                 241

TABLE 251            JULPHAR: COMPANY OVERVIEW               242

TABLE 252            JULPHAR: PRODUCTS OFFERED                243

TABLE 253            HALEON GROUP OF COMPANIES: COMPANY OVERVIEW          245

TABLE 254            HALEON GROUP OF COMPANIES: PRODUCTS OFFERED             246

TABLE 255            LES LABORATOIRES SERVIER: COMPANY OVERVIEW          247

TABLE 256            LES LABORATOIRES SERVIER: PRODUCTS OFFERED             248

TABLE 257            PRESTIGE CONSUMER HEALTHCARE: COMPANY OVERVIEW   249

TABLE 258            PRESTIGE CONSUMER HEALTHCARE: PRODUCTS OFFERED    250

TABLE 259            VIATRIS INC.: COMPANY OVERVIEW       252

TABLE 260            VIATRIS INC.: PRODUCTS OFFERED        253

TABLE 261            GALEN LIMITED: COMPANY OVERVIEW                 254

TABLE 262            GALEN LIMITED: PRODUCTS OFFERED 254

TABLE 263            MERIDIAN ENTERPRISES PVT. LTD.: COMPANY OVERVIEW          257

TABLE 264            MERIDIAN ENTERPRISES PVT. LTD.: PRODUCTS OFFERED             257

TABLE 265            COSETTE PHARMACEUTICALS: COMPANY OVERVIEW          259

TABLE 266            FLAGSHIP: COMPANY OVERVIEW             260

TABLE 267            OUBARI PHARMA: COMPANY OVERVIEW                 261

TABLE 268            LAVINA PHARMACEUTICALS PVT. LTD.: COMPANY OVERVIEW   262

TABLE 269            NORWELL: COMPANY OVERVIEW            263

LIST OF FIGURES

FIGURE 1              SUPPOSITORIES MARKET SEGMENTATION AND REGIONAL SCOPE            26

FIGURE 2              SUPPOSITORIES MARKET: YEARS CONSIDERED                 28

FIGURE 3              SUPPOSITORIES MARKET: RESEARCH DESIGN                 30

FIGURE 4              SUPPOSITORIES MARKET: KEY PRIMARY SOURCES             33

FIGURE 5              SUPPOSITORIES MARKET: INSIGHTS FROM PRIMARIES          34

FIGURE 6              BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS     34

FIGURE 7              BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,

AND REGION     35

FIGURE 8              SUPPOSITORIES MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2024      35

FIGURE 9              SUPPOSITORIES MARKET SIZE ESTIMATION: CAGR ESTIMATION, 2024               36

FIGURE 10            TOP-DOWN APPROACH                37

FIGURE 11            BOTTOM-UP APPROACH              37

FIGURE 12            DATA TRIANGULATION METHODOLOGY                 39

FIGURE 13            SUPPOSITORIES MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION)       42

FIGURE 14            SUPPOSITORIES MARKET, BY BASE, 2025 VS. 2030 (USD MILLION) 43

FIGURE 15            SUPPOSITORIES MARKET, BY PRESCRIPTION, 2025 VS. 2030 (USD MILLION)      43

FIGURE 16            SUPPOSITORIES MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)      44

FIGURE 17            SUPPOSITORIES MARKET, BY PATIENT TYPE, 2025 VS. 2030 (USD MILLION)      44

FIGURE 18            GEOGRAPHICAL SNAPSHOT OF SUPPOSITORIES MARKET             45

FIGURE 19            INCREASING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET     46

FIGURE 20            RECTAL SUPPOSITORIES SEGMENT AND US LED NORTH AMERICAN MARKET

IN 2024  47

FIGURE 21            RECTAL SUPPOSITORIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD            47

FIGURE 22            OLEAGINOUS/LIPOPHILIC BASES SEGMENT TO HAVE LARGEST MARKET SHARE DURING FORECAST PERIOD                 48

FIGURE 23            PRESCRIPTION SUPPOSITORIES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD        48

FIGURE 24            CHINA TO REGISTER HIGHEST GROWTH IN SUPPOSITORIES MARKET

FROM 2025 TO 2030          49

FIGURE 25            SUPPOSITORIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES         50

FIGURE 26            REVENUE SHIFT AND NEW REVENUE POCKETS FOR SUPPOSITORIES MARKET   56

FIGURE 27            AVERAGE SELLING PRICE OF RECTAL SUPPOSITORIES, BY KEY PLAYER,

2025 (USD)          57

FIGURE 28            SUPPOSITORIES MARKET: VALUE CHAIN ANALYSIS            59

FIGURE 29            SUPPOSITORIES MARKET: ECOSYSTEM ANALYSIS            60

FIGURE 30            SUPPOSITORIES MARKET: INVESTMENT AND FUNDING SCENARIO, 2020–2024 62

FIGURE 31            SUPPOSITORIES MARKET: PATENT ANALYSIS, JANUARY 2014–MAY 2025               65

FIGURE 32            TOP APPLICANT COUNTRIES/REGIONS FOR SUPPOSITORIES PATENTS,

JANUARY 2014–MAY 2025               66

FIGURE 33            SUPPOSITORIES MARKET: PORTER’S FIVE FORCES ANALYSIS           75

FIGURE 34            INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE          77

FIGURE 35            KEY BUYING CRITERIA, BY TYPE               78

FIGURE 36            AI USE CASES     81

FIGURE 37            NORTH AMERICA: SUPPOSITORIES MARKET SNAPSHOT          124

FIGURE 38            ASIA PACIFIC: SUPPOSITORIES MARKET SNAPSHOT          149

FIGURE 39            REVENUE ANALYSIS OF TOP FIVE PLAYERS IN SUPPOSITORIES MARKET,

2022–2024              191

FIGURE 40            SUPPOSITORIES MARKET SHARE ANALYSIS, 2024        192

FIGURE 41            RANKING OF KEY PLAYERS IN SUPPOSITORIES MARKET, 2024    194

FIGURE 42            SUPPOSITORIES MARKET: BRAND/PRODUCT COMPARISON   194

FIGURE 43            EV/EBITDA OF KEY VENDORS   195

FIGURE 44            YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK

BETA OF KEY VENDORS                195

FIGURE 45            SUPPOSITORIES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024         197

FIGURE 46            SUPPOSITORIES MARKET: COMPANY FOOTPRINT       198

FIGURE 47            SUPPOSITORIES MARKET: COMPANY EVALUATION MATRIX

(STARTUPS/SMES), 2024                203

FIGURE 48            SANDOZ GROUP AG: COMPANY SNAPSHOT (2024)    208

FIGURE 49            TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2024)      211

FIGURE 50            CIPLA: COMPANY SNAPSHOT (2024)        214

FIGURE 51            SANOFI: COMPANY SNAPSHOT (2024)    217

FIGURE 52            SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2024)      220

FIGURE 53            BAYER AG: COMPANY SNAPSHOT (2024)                 223

FIGURE 54            NOVARTIS AG: COMPANY SNAPSHOT (2024)                 226

FIGURE 55            ZYDUS GROUP: COMPANY SNAPSHOT (2024)                 229

FIGURE 56            BLISS GVS PHARMA LIMITED: COMPANY SNAPSHOT (2024)             231

FIGURE 57            CHURCH & DWIGHT CO., INC.: COMPANY SNAPSHOT (2024)             233

FIGURE 58            BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT (2024)             236

FIGURE 59            ADCOCK INGRAM: COMPANY SNAPSHOT (2023)                 238

FIGURE 60            ASPEN HOLDINGS: COMPANY SNAPSHOT (2023)                 241

FIGURE 61            JULPHAR: COMPANY SNAPSHOT (2024) 243

FIGURE 62            HALEON GROUP OF COMPANIES: COMPANY SNAPSHOT (2024)             246

FIGURE 63            LES LABORATOIRES SERVIER: COMPANY SNAPSHOT (2023)             248

FIGURE 64            PRESTIGE CONSUMER HEALTHCARE: COMPANY SNAPSHOT (2024)      250

FIGURE 65            VIATRIS INC.: COMPANY SNAPSHOT (2024)                 253

MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。

※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

ライセンスタイプ4

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
  • コーポレートライセンス
    • 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
  • エンタープライズサイトライセンス
    • 特別ライセンスです。適用範囲についてはお問合せください。
• 納品形態
  • Eメール
• 納期
  • 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
• 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
• ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11

MarketsandMarkets  出版レポート一覧